Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus

Vaccine

Volumn 25, Issue 42, 2007, Pages 7441-7449

  Reap, Elizabeth A ^a   Morris, John ^a   Dryga, Sergey A ^a   Maughan, Maureen ^a   Talarico, Todd ^a   Esch, Robert E ^b   Negri, Sarah ^a   Burnett, Bruce ^a   Graham, Andrew ^a   Olmsted, Robert A ^a   Chulay, Jeffrey D ^a  

^a AlphaVax Inc   (United States)

^b Greer Laboratories   (United States)

Author keywords

Cellular immunity; Cytomegalovirus vaccine; Manufacturing process; Toxicology testing

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GAMMA INTERFERON; GLYCOPROTEIN B; HYBRID PROTEIN; PLACEBO; SYNAPTOTAGMIN I; VIRUS VECTOR;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; MALE; MOUSE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; REPLICON; SERODIAGNOSIS; T LYMPHOCYTE; VIRUS REPLICATION;

ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; FEMALE; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; MALE; MICE; MICE, INBRED BALB C; PLASMIDS; RABBITS; REPLICON; VACCINES, SYNTHETIC;

EID: 34748921158     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.016     Document Type: Article

References (30)

1. Staras S.A., Dollard S.C., Radford K.W., Flanders W.D., Pass R.F., and Cannon M.J. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 43 9 (2006) 1143-1151
2. Hebart H., and Einsele H. Clinical aspects of CMV infection after stem cell transplantation. Hum Immunol 65 5 (2004) 432-436
3. Rowshani A.T., Bemelman F.J., van Leeuwen E.M., van Lier R.A., and ten Berge I.J. Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 79 4 (2005) 381-386
4. Boeckh M., Fries B., and Nichols W.G. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 8 Suppl. 5 (2004) 19-27
5. Limaye A.P., Bakthavatsalam R., Kim H.W., Kuhr C.S., Halldorson J.B., Healey P.J., et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 78 9 (2004) 1390-1396
6. Arvin A.M., Fast P., Myers M., Plotkin S., and Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis 39 2 (2004) 233-239
7. Britt W.J., Vugler L., and Stephens E.B. Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB). J Virol 62 9 (1988) 3309-3318
8. Speckner A., Glykofrydes D., Ohlin M., and Mach M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J Gen Virol 80 Pt 8 (1999) 2183-2191
9. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333 16 (1995) 1038-1044
10. Bunde T., Kirchner A., Hoffmeister B., Habedank D., Hetzer R., Cherepnev G., et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 201 7 (2005) 1031-1036
11. Schleiss M.R., Lacayo J.C., Belkaid Y., McGregor A., Stroup G., Rayner J., et al. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 195 6 (2007) 789-798
12. Reap E.A., Dryga S.A., Morris J., Rivers B., Norberg P.K., Olmsted R.A., et al. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1 and gB proteins. Clin Vaccine Immunol 14 6 (2007) 748-755
13. Kamrud K.I., Custer M., Dudek J.M., Owens G., Alterson K.D., Lee J.S., et al. Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 360 2 (2007) 376-387
14. Wagner B., Kropff B., Kalbacher H., Britt W., Sundqvist V.A., Ostberg L., et al. A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. J Virol 66 9 (1992) 5290-5297
15. Meyer H., Sundqvist V.A., Pereira L., and Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 73 Pt 9 (1992) 2375-2383
16. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., and Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239 2 (1997) 389-401
17. Talarico T., Maughan M., Pancorbo B., Ruiz J., and Graham A. Development and manufacture of alphavaccines. Bioprocessing Fall (2006) 8-14
18. Elek S.D., and Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1 7845 (1974) 1-5
19. Plotkin S.A., Starr S.E., Friedman H.M., Brayman K., Harris S., Jackson S., et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 114 7 (1991) 525-531
20. Kemble G., Duke G., Winter R., and Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 70 3 (1996) 2044-2048
21. Pass R.F., Duliege A.M., Boppana S., Sekulovich R., Percell S., Britt W., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 180 4 (1999) 970-975
22. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183 8 (2001) 1171-1179
23. Bernstein D.I., Schleiss M.R., Berencsi K., Gonczol E., Dickey M., Khoury P., et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 185 5 (2002) 686-690
24. Kaslow D. Multi-valent CMV DNA vaccines for use in transplant settings. Proceedings of the 10th International CMV/Betaherpesvirus Workshop (2005) [abstract 10.08]
25. Selinsky C., Luke C., Wloch M., Geall A., Hermanson G., Kaslow D., et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccine 1 1 (2005) 16-23
26. Plotkin S.A. Is there a formula for an effective CMV vaccine?. J Clin Virol 25 Suppl. 2 (2002) S13-S21
27. MacDonald G.H., and Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J Virol 74 2 (2000) 914-922
28. Kowalski J., Adkins K., Gangolli S., Ren J., Arendt H., DeStefano J., et al. Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D. Vaccine 25 12 (2007) 2296-2305
29. Chulay J., Burke D., Karim S.S.A., Russell N., Wecker M., Allen M., et al. Safety and immunogenicity of an alphavirus replicon HIV Gag vaccine (AVX101) in healthy HIV-uninfected adults. AIDS Vaccine 06 (2006) P11-09
30. Knezevic I, Griffiths E. WHO Expert Committee on Biologcial Standardization. WHO Technical Report Series 2004; 926, 1-109.